Yale University

EliScholar – A Digital Platform for Scholarly Publishing at Yale
Yale School of Nursing Digital Theses

School of Nursing

1-1-2016

Joining Forces:establishing A Cardio-Oncology Program
Caroline Austin-Mattison
Yale University, caroline.austin-mattison@yale.edu

Follow this and additional works at: https://elischolar.library.yale.edu/ysndt

Recommended Citation
Austin-Mattison, Caroline, "Joining Forces:establishing A Cardio-Oncology Program" (2016). Yale School
of Nursing Digital Theses. 1022.
https://elischolar.library.yale.edu/ysndt/1022

This Open Access Thesis is brought to you for free and open access by the School of Nursing at EliScholar – A
Digital Platform for Scholarly Publishing at Yale. It has been accepted for inclusion in Yale School of Nursing Digital
Theses by an authorized administrator of EliScholar – A Digital Platform for Scholarly Publishing at Yale. For more
information, please contact elischolar@yale.edu.

JOINING FORCES: CREATING A CARDIO-ONCOLOGY PROGRAM

Submitted to the Faculty
Yale University School of Nursing

In Partial Fulfillment
of the Requirements for the Degree
Doctor of Nursing Practice

Caroline Austin-Mattison
March 6, 2016
This capstone is accepted in partial fulfillment of the requirements for the degree Doctor of
Nursing Practice.

Jessica Shank Coviello
Date here

March 6, 2016

ii

This material may be protected by Copyright Law (Title 17, US Code). Brief quotations are
allowable without special permission, provided that accurate acknowledgement of source is
made. Requests for permission for extended quotation from or reproduction of this manuscript
in whole or in part must be granted by the copyright holder.

Signed: Caroline Austin-Mattison
March 6, 2016

iii

Running head: JOINING FORCES

Joining Forces: Establishing a cardio-oncology clinic

Joining Forces

2

Abstract
Patients have been surviving cancer diagnoses at a steady increasing rate over the past
few decades. In spite of the encouraging decline in cancer morbidity, the cardiovascular effect of
some chemotherapy medications is concerning. Moreover, even though there is extensive
knowledge in regards to the pathophysiology and increased risk of cardiotoxicity, there is a lack
of specific guidelines and adequate cardio-oncology programs focused on reducing
cardiovascular risks or disease in patients undergoing cancer treatment. The high incidence of
both cardiovascular disease (CVD) and cancer warrants the collaboration of oncology and
cardiology providers to screen, treat promptly, and thereby provide an opportunity to improve
cancer patients’ quality of life both during treatment and extended through cancer survivorship.
We found no designated cardio-oncology programs in our geographical area from Poughkeepsie
to New York City; therefore a feasibility project was developed in collaboration with a
cardiologist and a cardiology nurse practitioner specializing in oncology in our institution. The
project included the development and implementation of a cardio-oncology program in a
suburban community cardiology practice in order to provide service in this area to breast cancer
patients at risk for cardiotoxicity. The RE-AIM framework was employed to guide the project
and enhance the translation of research into practice through planning and execution.

Role of cardio-oncology
The survival rate of patients with cancer has increased over the past 25 years in the
United States. The 5-year relative survival rate of patients diagnosed with cancer between the
years 1975 and 1977 was 49 percent for all cancer sites and this number improved to 68 percent
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between 2004 and 2010. When assessed by ethnicity, a 69 percent improvement in Caucasians
and a 62 percent improvement in African Americans were noted for cancer of all sites. Breast
cancer has a relative survival rate of 92 percent in Caucasians and 80 percent in African
Americans (American Cancer Society, 2015). However, with increased survival rates comes an
increased risk of cardiotoxicity.
Five percent of cancer patients develop heart failure, with the threat found to be higher in
those patients with cardiovascular risk factors such as hypertension (HTN) and hyperglycemia.
In a study by Khouri et al, women with early-stage breast cancer had a 30% increased risk of
cardiac events, for example, of which congestive heart failure (CHF) was the most common.
There are over 62.9 cardiac events in those patients per 10,000 patient-years (Khouri, et al.
2012). However, control of these cardiovascular risks and the early heart failure treatment can
result in complete recovery (Cardinale et al., 2010).
The increased incidence of cardiovascular disease is a result of the adverse effects of
chemotherapy agents. Patients treated with chemotherapy, especially anthracyclines, are prone to
increased CV risk and may develop cardiomyopathy, heart failure, or myocardial infarction up to
20 years after treatment (Cardinale et al., 2013). The role of anthracycline in breast cancer
treatment is continuing to expand due to its efficacy and tumor response, especially when used
with newer anti-tumor medications such as taxanes and trastuzumab (Herceptin) (Pouillart,
2004); therefore, it is important to assess for CVD and closely monitor patients at increased risk
so they can receive appropriate cancer treatment without the increased risk of cardiotoxicity. The
focus can no longer be solely on eradicating cancer without concern for the long-term effects of
CVD. Because cardiac toxicity can occur at the start of chemotherapy administration, as well as
months or years later, the cardiology provider’s role is to work with the oncologist and monitor
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for signs of cardiotoxicity. The severity of cardiotoxicity depends on molecular sites of action,
immediate or cumulative dose of chemotherapy, methods of administration, presence of other
comorbidities and demographics (Yeh, et al., 2004)). During the surveillance phase, if a patient
shows signs of cardiac toxicity, prompt intervention is warranted.
This early intervention will be possible only when providers work collaborativel y to
provide cardio-oncology care. Cardio-oncology addresses the cardiovascular side effects of
cancer therapy to improve the quality of life for cancer survivors. The need for this specialty is
continuing to increase with improvement in cancer risk factor identification, early screening,
detection, and the success of new cancer treatments. As such, it is necessary to establish a cardiooncology program that ensures the comprehensive management of any comorbid cardiovascular
issues a patient has, in addition to any other problems associated with the patient’s cancer, in
order to maintain optimal quality of life throughout survivorship.
Evidence for early integration of cardio-oncology care
There are currently no cardio-oncology specific guidelines that address the screening or
management of chemotherapy- induced cardiotoxicity (symptomatic or asymptomatic) or the
progression of cardio-toxic left-ventricular dysfunction. However, current evidence makes it
clear that prompt intervention improves outcomes and quality of life following the use of
chemotherapy. Currently, the American Heart Association and American College of Cardiology
(AHA/ACC) 2013 guidelines for the management of heart failure are being used to treat
chemotherapy-induced cardiotoxicity (Yancy et al., 2013). The European Society for Medical
Oncology did develop clinical practice guidelines in 2012 specifically for cancer patients, but
those guidelines were based mostly on consensus. No randomized control trials were used to
determine approaches (Cardoso et al., 2014).
4
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Despite a lack of standardized approaches, there is evidence that the early treatment of
patients who develop anthracycline chemotherapy- induced cardiotoxicity may result in the full
recovery of left ventricular (LV) function with improved cardiac outcomes (Cardinale et al.,
2010). Figure 1 demonstrates a possible four-fold decrease in LV recovery based on how long it
takes for treatment to be initiated after chemotherapy ended. Of the patients who were treated
within 2 months of the end of chemotherapy, 64% had full recovery of LV function. For every 2
months that treatment was delayed thereafter, the chance of full recovery decreased significantly.
(Cardinale et al., 2010).

Figure 1-Permission granted from Daniela Cardinale, European Institute of Oncology 12/2015

As such, it is clear that the optimal timing of heart failure diagnostic evaluation, selection
of chemotherapy agent based on cardiovascular comorbidities, and utilization of cardioprotective regimens may result in longer survival and better quality of life. (Albini et al., 2010).
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Patients who develop cancer and cardiac disease demonstrate varied outcomes depending on
which specialty provider they see first. For example, if the patient sees the oncologist first, then
cardiovascular risk factors might not be assessed and underlying cardiac disease may be missed
(Albini et al., 2010). The risk of heart disease superimposed on a cancer diagnosis acts as a
compelling argument for collaborative practice between the oncologist and the cardiologist early
in the treatment process (see Team Model, Figure 2). The use of a “sliding door” approach, in
which both providers consider risks and coordinate care based on patient age, prior use of
anthracycline, uncontrolled hypertension, uncontrolled diabetes, and/or cardiac disease, is
essential in order to improve outcomes for these kinds of comorbidities (Albini et.al. 2010).
Benefits of a cardio-oncology clinic
The American Heart Association recommends close monitoring of cardiac function for
adults undergoing anthracycline therapy alone or in combination. Unfortunately, it fails to
provide a specific guide as to how often patients need to be followed and which methods and
thresholds should be used (Sawaya, H., Plana, J. & Scherrer-Crosbie, M, 2011]). Therefore,
cardio-oncology providers who focus on cancer survivorship should be accessible to all patients
who are at risk for cardio-toxicities associated with chemotherapy.

The creation of a cardio-oncology program
The need for a cardio-oncology program in the Mid Hudson Valley region is indisputable
given the number of breast cancer survivors locally. In Dutchess County, the number of cases for
all malignant tumors among females averaged 472.8 per 100,000 annually during the same
period (New York Cancer Registry, 2014). Despite the need for these services, a search of
cardio-oncology clinics revealed none within a 100-mile radius of the Hudson Valley. Given the
6
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dearth of cardio-oncology programs in the area, this project aimed to bring to fruition a
sustainable cardio-oncology program to benefit breast cancer survivors.
A needs assessment, performed by a nurse practitioner, was the first step in identifying
the lack of access to comprehensive cardiology care among breast cancer survivors. Patients
reported that they were experiencing symptoms related to cardio toxicity post-chemotherapy.
The oncologists and administrators readily supported the initial formation of a cardio-oncology
clinic for women with breast cancer. The program that was created utilized a proactive approach
to managing patients’ needs identified from the assessment. Aspiring to provide care for the
whole patient, coordination, planning, and education of patients on cancer and cardiac diagnosis
and treatment, was key to creating the program.
The RE-AIM framework
The RE-AIM framework was used to guide the project and enhance the translation of
research into practice through planning and execution. The RE-AIM model was applied as a
structure to improve consistency in cardio-oncology disease management based on existing
research in various settings. The framework has also been used to translate research into practice
and to assist with program evaluation. The five steps of the RE-AIM model are: Reach,
Effectiveness, Adoption, Implementation, and Maintenance (Glasgow, Boles, & Vogt 1999).
This project was designed to incorporate three of those steps: Reach, Adoption, and
Implementation.
The first step of the framework, Reach, was accomplished through a process that
involved reaching the patients so they could be assessed and evaluated for their at risk status of
cardiovascular disease. This process included increasing oncology provider’s awareness of the
importance of early cardiovascular screening and soliciting their referrals for consultation. The
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goal was to improve access and consistency while reaching the target population: patients
diagnosed with breast cancer requiring cancer treatment and oncology services. The cardiologist
has been practicing in his specialty and the Hudson valley region for three years and the APRN
has experience working in cardiology for 9 years. Both providers had a goal to increase patient
referrals, pre-treatment assessment and cardiovascular treatment as needed during and post
chemotherapy treatment. The number of patients with breast cancer over a six-month period
varied weekly, however most patients had a diagnosis of breast cancer and others forms included
lung, liver adenocarcinoma and one patient with the diagnosis of multiple myeloma.
The Adoption of this project occurred as providers focused on screening and treating
CVD risks in a timely manner.

It involved the growth of the cardio-oncology program and it

increased as women were referred for screening for pre-oncology treatment. The Implementation
of this essential cardio-oncology program became possible with stakeholder support from
administration and the medical oncologists in establishing this designated program in the Mid
Hudson Valley area. Maintenance of the program requires an ongoing effort to continually
increase and achieve pre-cancer treatment screening and routine follow-up care. Table 1 provides
examples demonstrating the application of the RE-AIM framework in developing this cardiooncology program.
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Table 1: Examples of Application of RE-AIM Steps in Cardio-Oncology
RE-AIM Steps

Strategies to Achieve Step Sources of Evidence

Reach refers to the
proportion of
representativeness of the
population targeted by the
innovation.

Recruitment of patients
through community
outreach, online blog, and
educational presentations
for providers.

Adoption refers to the
proportion of organizations
or settings that adopt the
innovation.

Implementation refers to
treatment fidelity or evidence
that the intervention could be
implemented as intended in
the proposed settings.

Maintenance refers to longterm adherence to the
intervention and integration
of the intervention to routine

Stakeholder willingness to
provide a designated clinic
day for cardio-oncology
patients. Integration of the
cardio-oncology program
focusing on primary and
secondary prevention.

Evidence of change in
scheduling patients for
follow-up appointments,
designated 3D
echocardiogram
sonographer to perform
studies on oncology
patients.

Gradual increase in number of
patients referred for cardiac care
for pre-treatment screening,
during cancer treatment, and
post-treatment follow- up.
Measurement of the number of
patients who received cardiooncology transthoracic
echocardiogram, CV assessment
and lipid profile. Increase in the
number of patients who were
started on a statin for
hyperlipidemia, ASA for CAD
risk, treatment for HTN, early
LV dysfunction and those
patients identified as having 1 or
more CV risk factors.
Stakeholder support and
adherence to a weekly clinic
schedule. Clinic schedulers are
accommodating to oncology
patients. Delivery of care is
“patient-centered,” weighs risks
and benefits.

Provider training internally and
externally. Use of cardiooncology protocols to
standardize care. Cardiology
provider communicates
frequently with oncology
providers to discuss changes and
make recommendations based
on CV assessment.

The clinic will be evaluated
every 6 months to
determine sustainability
and maintenance over time

9
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Increased numbers of patients
who receive cardiovascular
screening and prompt treatment
of cardiovascular complications
through collaboration.

Table 1 Permission for use and modification obtained from Barbara Resnick, PhD, Sonya
Ziporkin Gershowitz Chair in Gerontology University at the Maryland School of Nursing.
“Translation of function-focused care to assisted-living facilities”.
A successful program requires ongoing interaction among cardio-oncologists,
oncologists, nurses, and patients. The feasibility of developing and implementing this initial
program was organized using The care team model (Figure 3), where integrated services were
provided by a cardio-oncologist and advanced practice registered nurse (APRN). Developing the
program involved orienting providers to the need for the program and teaching them about the
diagnostic and management of cardio-oncology toxicities. Training was provided to oncologists,
nurses, and support staff such as medical assistants, technicians, administrative staff, and leaders
in the practice. Lectures were provided in various forums, such as an allied health provider
education day, hospital symposia, and small group meetings. Meetings with leaders of the
cardiology and community oncology practices were scheduled at regular intervals to increase
awareness and maintain interest in the program. A team effort leads to better-coordinated cardiooncology appointments and diagnostic tests, and provides consistently timely scheduling and
embedded time slots for patient education and engagement. Advanced practice registered nurse
involvement in this program also improved clinical flow. The APRN saw stable patients during
follow-up visits independently (may vary based on institution or state policies) and began initial
visit assessments and data collection. This approach provided the cardio-oncologists an
opportunity to see more acutely ill patients.
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Outcomes
Teaming the APRN with a local cardio-oncology provider for individualized cardiac risk
assessment has proven to be beneficial. Under a collaborative care regimen, patients received
individualized care that prevented further deterioration and lead to improvement in cardiac
function. The screening in this program was shown to not only help prevent chemotherapyinduced cardiotoxicity, but also prevented high-risk patients from receiving more toxic
chemotherapeutic agents. Providers were informed and could use this information to offer
choices based on risks versus benefits, with an emphasis on improving disease prognosis and
quality of life. The cardiology provider’s focus on reducing or controlling risk factors such as
uncontrolled HTN, hyperlipidemia, and uncontrolled diabetes before and during treatment was a
key element in this program. As a result, the program has been judged to be feasible and
effective. Consequently, the cardio-oncology program is now a local service for Hudson Valley
residents (See Figure 2 for the recommended cardiovascular monitoring algorithm).
Barriers to collaborative care
Although this project demonstrated that women with breast cancer were referred and assessed for
cardiovascular disease; there were some obstacles to increasing referrals and getting all oncology
providers on board. This initial project was limited to women with breast cancer so a limited
number of medical oncologists participated. Patients with other types of cancer scheduled for
chemotherapy may be equally at risk for cardio toxicities so the referral network needs to be
expanded to include other types of oncologists. As the program is expanded to patients with
other cancers, additional efforts will be needed to obtain both institutional and provider buy-in. It
is well recognized that a lack of institutional support may hinder the growth and success of any
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cardio-oncology program. (Okwuosa & Barac, 2015). There is also a need to continue to develop
evidence-based standards because there is little consensus on a standard of practice. (Okwuosa
& Barac, 2015). There is also a lack of clinical trials demonstrating outcomes associated with
cardio-oncology management, which may limit the oncologist’s willingness to refer to a
cardiologist. Referring patients with two or more risk factors may not seem to be a priority for
some providers; however, pre-existing HTN and diabetes should be concerning in women
undergoing chemotherapy, as the Framingham Heart Study general cardiovascular risk profile
establishes HTN, smoking, dyslipidemia, and diabetes as major CVD risk factors (D’Agostino et
al., 2008). Despite the barriers encountered during the development of the project, working with
the targeted population and applying a commonly- used care model was valuable in its
implementation.
Discussion
It is well established that the number of cancer survivors is increasing. Therefore,
ensuring the best quality of life for patients following a cancer diagnosis and treatment is
important. Because many of the patients treated for cancer, fear recurrence and are concerned
with their long-term wellness, there is an opportunity for cardio-oncology providers to impact
survivorship. Providers interested in decreasing cardiac events and promoting wellness among
cancer survivors need to shift their focus to include early screening and treatment. Cardiooncology care should not be restricted to those who have already developed cardiac
complications. The cardio-oncology program described here is not only closing the gap between
CV assessment, prevention, and prompt treatment, but also providing a necessary local service
for improving the wellness and quality of life of patients after their breast cancer treatment.
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Cardiovascular monitoring of cancer patients

Figure 2 Adapted from: JNCI 2010. Approval for use from Adriana, Albini; permission from
Oxford University Press.
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Figure 3-Cardio-Oncology Care Team model demonstrating the interactive process between
cardio-oncologists, oncologists, patients, health care administrators and education required for
integrated patient care. Permission granted for use by Dr. Okwuosa T. M, Burgeoning CardioOncology Programs Challenges and Opportunities for Early Career Cardiologists/Faculty
Directors. Journal of American College of Cardiology, 66 (10), 1193-1197.
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